View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 28, 2021

Unmet needs and opportunities in HER2+ breast cancer

Approvals and label expansions for certain therapies are positioned to partially counter some of the unmet needs in the HER2+ breast cancer space.

By GlobalData Healthcare

The treatment of human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterised by a moderate level of unmet clinical need. It was one of the first oncology indications to benefit from the development of targeted therapies, in the form of Herceptin (trastuzumab), which was first approved by the US Food and Drug Administration (FDA) in 1998. With the introduction of Herceptin in both earlier and advanced settings, in addition to the introduction of effective antibody-drug conjugates, the treatment paradigm and the subsequent improvements in patient survival have positively deviated from other underserved oncology indications.

Key opinion leaders (KOLs) interviewed by GlobalData highlight that while there is still a need for improved treatment options, in particular curative interventions and treatments for patients with brain metastases, there is also an emphasis on patient quality of life. Other notable unmet needs include the need to stratify patients by specific molecular profile and how to effectively treat intratumour heterogeneity. Label expansions for agents such as Tukysa (tucatinib) and Enhertu (trastuzumab deruxtecan), along with the approval of agents such as trastuzumab duocarmazine, are positioned to partially counter some of the unmet needs in this space. The unmet needs and opportunities in the HER2+ space are highlighted below.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU